AKILA BOOZER: Open Payments
NPI 1316594724 · GREENWOOD, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,478 in 138 payments from 14 companies in 2025. Trend: 2023 $2,412 · 2024 $1,701 · 2025 $2,478
Food & beverage: $2,478
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $471 |
| Neurocrine BioSciences, Inc. | 15 | $382 |
| ABBVIE INC. | 24 | $265 |
| E.R. Squibb & Sons, L.L.C. | 14 | $255 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $218 |
| Alkermes, Inc. | 9 | $198 |
| Teva Pharmaceuticals USA, Inc. | 14 | $187 |
| Janssen Pharmaceuticals, Inc | 10 | $146 |
| Supernus Pharmaceuticals, Inc. | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
Products named: INGREZZA, COBENFY, VRAYLAR, ABILIFY MAINTENA, CAPLYTA, REXULTI, INVEGA SUSTENNA, UZEDY.
Industry payments across SC — which companies pay providers there.
